Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:activities |
inhibitor of RAF/ MEK pathway
|
| gptkbp:clinical_trial |
Phase 1/2
|
| gptkbp:developed_by |
Verastem Oncology
|
| https://www.w3.org/2000/01/rdf-schema#label |
VS-6766
|
| gptkbp:indication |
gptkb:healthcare_organization
KRAS-mutant tumors |
| gptkbp:ingredients |
C20 H22 Cl N5 O2 S
|
| gptkbp:is_tested_for |
clinical trials
|
| gptkbp:is_used_for |
gptkb:healthcare_organization
|
| gptkbp:manager |
oral
|
| gptkbp:research_focus |
oncology
|
| gptkbp:social_structure |
gptkb:Cloud_Computing_Service
|
| gptkbp:status |
investigational drug
|
| gptkbp:targets |
RAF kinase
|
| gptkbp:type_of |
2034246-12-0
|
| gptkbp:bfsParent |
gptkb:Verastem,_Inc.
|
| gptkbp:bfsLayer |
6
|